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A B S T R A C T
Bone morphogenetic protein (BMP) belongs to transforming growth factor-β superfamily. To date, more
than 20 BMPs have been identiﬁed in humans. BMPs play a critical role in embryonic and postnatal de-
velopment, and also in maintaining homeostasis in different organs and tissues by regulating cell
differentiation, proliferation, survival and motility. They play important roles in the development and
progression of certain malignancies, including prostate cancer, breast cancer, lung cancer, etc. Recently,
more evidence shows that BMPs are also involved in tumour associated angiogenesis. For example BMP
can either directly regulate the functions of vascular endothelial cells or indirectly inﬂuence the angio-
genesis via regulation of angiogenic factors, such as vascular endothelial growth factor (VEGF). Such crosstalk
can also be reﬂected in the interaction with other angiogenic factors, like hepatocyte growth factor (HGF)
and basic ﬁbroblast growth factor (bFGF). All these factors are involved in the orchestration of the an-
giogenic process during tumour development and progression. Review of the relevant studies will provide
a comprehensive prospective on current understanding and shed light on the corresponding therapeu-
tic opportunity.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Blood vessels form a complex network that transports blood, nu-
trients, oxygen and metabolic waste through our bodies, from the
respiratory and digestive systems to the kidneys and lungs – for dis-
charge and exchange. These blood vessels also transfer messages
from one organ/tissue to other distant parts of the body, via hor-
mones, proteins and other messengers. Formation of new blood
vessels (vasculogenesis/angiogenesis) is an essential process for em-
bryonic and postnatal development and also tissue repair (wound
healing and endometrial angiogenesis during the menstrual cycle
in women). Aberrant angiogenesis has been implicated in differ-
ent disorders. Insuﬃcient new vasculature may lead to defect in
development and more suffering from certain disorders such as cor-
onary heart disease, stroke and chronic wound [1–3]. Uncontrolled
and excessive angiogenesis can result in haemangioma and under-
lie certain pathological changes in patients with certain chronic
diseases such as diabetes [4–6]. Angiogenesis also contributes to
tumour growth and provides a pathway for the dissemination of
malignant tumour cells [7,8]. This has been one of the most heavily
invested research areas for different disorders, in particular for treat-
ment of various solid tumours to stop tumour growth and prevent
the haematogenous dissemination of cancer cells [9].
Angiogenesis is a complex process consisting of multiple steps
which require a variety of growth factors and cytokines to initiate
and coordinate in a spatiotemporal setting. Hypoxia is the primary
factor for triggering angiogenesis via hypoxia inducible factors (HIFs),
which subsequently upregulate pro-angiogenic factors. Pro-
angiogenic factors such as VEGF, FGF, TNF-α, and certain interleukins
can be produced by cancer cells, stromal cells, inﬂammatory cells
and endothelial cells. These factors promote angiogenesis either by
endothelial cell sprouting from pre-existing vessels [10] or by re-
cruitment of endothelial progenitor cells (EPCs) derived from
circulating bone marrow cells [11]. The formation of new blood
vessels involves a series of coordinated biological processes such
as cell proliferation, guided migration, differentiation and cell–
cell communication [12]. There are three ways of forming new
capillaries: sprouting growth, longitudinal division and intussus-
ceptive growth [13,14].
Sprouting angiogenesis, which is the most commonly studied
mechanism, starts with a tip cell that moves along a gradient of pro-
angiogenic factors and degradation of basementmembrane, followed
by the growth of a trunk with proliferating endothelial stalk cells.
These endothelial cells will form a lumen, recruit pericyte, ﬁbro-
blast and smooth muscle cells (for bigger vessels) to surround the
nascent vessel, and so the basement membrane will be reformed.
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The tip cells are essential at the start of sprouting by degrading
basement membrane, migrating through extracellular matrix (ECM)
[10]. The elongation of the new vessel relies on the proliferation
of stalk cells which immediately follow the tip cells. Eventually, when
tip cells encounter the tip of other sprouts, the migration will be
inhibited and new cell–cell adhesionwill be established at the joining
point. The formation of a lumen consists of: the recruitment of
pericytes and ﬁbroblasts to new vessels, the deposition of ECM pro-
teins and the terminal differentiation of ECs leading to vessel
maturation and quiescence [12].
Angiogenesis is an important event during the development and
progression of both primary and secondary tumours [15,16]. Tumour
associated angiogenesis is pivotal for a solid tumour to grow beyond
a size (2–3 mm) that is restricted by interspatial diffusion of nu-
trients and it also provides a fast and easier route for cancer cells
to spread to other parts of the body. Such angiogenesis is affected
by multiple factors and various cells in the tumour [9]. Bone mor-
phogenetic proteins (BMPs) belong to the transforming growth
factor-beta (TGF-β) superfamily. They are involved in angiogen-
esis by either directly acting on endothelial cells or mediating
interactions among different cell types in the tumour microenvi-
ronment [17,18]. In the current review, we are trying to focus on
these two areas to highlight the importance they have in tumour
associated angiogenesis and therapeutic potential.
BMP and BMP signalling
To date, more than 20 BMPs have been identiﬁed. These BMPs
play vital roles in intramembraneous/endochondral bone forma-
tion and formation of cartilage. BMPs are also essential for certain
developmental processes and homeostasis of various tissues and
organs such as teeth, kidneys, prostate, breasts, skin, hair, muscle,
heart and neuron [18–25].
BMP precursor proteins have an amino-terminal pro-region and
a carboxy-terminal ligand containing seven conserved cysteines
[26–28]. Six cysteines at the C-terminal tail construct a cysteine knot,
whilst the seventh cysteine contributes to the dimerisation of ligands
[29]. BMP precursor proteins can be proteolytically activated at the
sequence of R-X-K/R-R or R-X-X-R by proprotein convertases (PCs),
such as furin, proprotein convertase subtilisin/kexin type 6 (PCSK6)
and proprotein convertase subtilisin/kexin type 5 (PCSK5) [30–33].
The pro-region of the precursor BMP protein stabilises the pro-
cessed ligands [31]. Following the cleavage, BMP ligands can form
homodimer and heterodimer molecules. Certain heterodimers such
as BMP-4/-7, BMP-2/-6, BMP-2/-7 and BMP7-/GDF-7 tend to bemore
effective than their homodimers [29,34–36].
BMP signal transduction
BMP signals are mediated by type I and type II serine/threonine
kinase receptors. Six of the type I receptors and three of the type
II receptors have been shown to mediate BMP signalling [24].
BMPR1A, BMPR1B and BMPR2 are speciﬁc to the BMPs, whilst
ACVRL1, ACVR1, ACVR1B, ACVR2B, and ACVR2A are the receptors
shared with activin; TGFBR1 (ALK5) is known as the type I recep-
tor for TGF-β1, 2 and 3. Both type I and type II receptors consist of
a N-terminal extracellular ligand binding domain, a single trans-
membrane region, and a C-terminal serine/threonine kinase domain
[37]. BMP ligands exhibit higher aﬃnity with type I receptor. Upon
binding with BMP ligands, a ligand–receptor complex consisting of
a homodimer/heterodimer of BMP ligands, type-I and type-II re-
ceptors are formed rapidly. The type-II receptors transphosphorylate
the GS domain of the type-I receptors leading to an activation of
downstream cascades [38].
Smad proteins are important intracellular molecules mediat-
ing signals from the BMP receptors. The Smad family comprises
receptor regulated Smads (R-Smads, Smad-1, -2, -3, -5 and -8),
commonmediator Smads (Co-Smad, Smad-4), and inhibitory Smads
(I-Smads, Smad-6 and -7) [39,40]. R-Smads 1, 5 and 8 are sub-
strates of the type I receptors (ALK-1, ALK-2, ALK-3 and ALK-6), whilst
R-Smads 2 and 3 are substrates of the type I receptors (ALK-4, ALK-5
and ALK-7) [40–43]. Smad2 and 3 in complex with Smad4 bind spe-
ciﬁcally via their MH1 domains to Smad binding elements (SBE),
i.e. AGAC/GTCT at promoter of target genes [44]. Smad1 binds with
low aﬃnity to SBEs and preferentially binds to a GC-rich se-
quence, such as GCCGNCGC [45].
Binding of BMP ligand to preformed hetero-oligomeric com-
plexes (PFC) leads to activation of the Smad dependent pathway
[39,46]. The pathway-restricted Smads (R-Smads, Smads1, 2, 3, 5
or 8) are recruited and translocated into nuclei with assistance of
Smad-4 and regulates the transcription of target genes; this is known
as the Smad dependent pathway. Upon activation, the Smad-
complex will translocate into the nucleus, R-Smads will interact with
transcriptional coactivators and repressors to regulate expression
of target genes, including ID1, Smad-6 and -7.
BMPs have a higher aﬃnity with the type-I receptors. Thus, BMP
ligand can also bind to ALK3 or ALK6, and then recruits BMPRII into
a hetero-oligomeric complex (BMP-induced signalling complexes,
BISC); this leads to the activation of the Smad independent pathway
[39,46]. X-linked inhibitor of the apoptosis protein (XIAP) func-
tions as an adaptor protein bridging between the type I receptor
and TGF-ß activated binding protein (TAB1/2/3), which is an acti-
vator of the MAPKKK TGF-ß activated tyrosine kinase 1 (TAK1)
[47–49]. TAK1 can subsequently activate mitogen-activated protein
kinase (MAPK) pathways [46,50,51]. TAK1 can also activate Jun
N-terminal kinases (JNKs), NF-kappaB (NF-κB), and Nemo-like kinase
(NLK) [52–54].
Regulation of BMP signalling
BMP signalling can be regulated extracellularly during the process
of ligand binding to the receptors, or intracellularly during signal
relay and regulation of their target genes (Fig. 1). The most impor-
tant molecules that inﬂuence BMP signalling extracellularly are BMP
antagonists including Noggin, Follistatin, Gremlin, Chordin, Chordin-
like, etc. The antagonists can competitively bind to BMP receptors.
Expression of BMP antagonists can be induced by BMP ligands. For
example, noggin expression in osteoblasts can be induced by BMP2,
4 and 6 [55]. This feedback regulation of BMP antagonists has also
been observed in prostate cancer cells [56]. Such feedback regula-
tion helps cells to justify their response to BMP ligands which also
operate through regulation of the pseudoreceptor and I-Smads
[57,58].
Along with the BMP antagonists, co-receptors and
pseudoreceptors can also coordinate binding of BMP ligands to the
receptors. BMP and activin membrane bound inhibitor (BAMBI) is
a pseudoreceptor for serine-threonine kinase receptor which lacks
the intracellular serine/threonine kinase domain. Binding of BAMBI
to the ligands can inhibit subsequent signalling [59]. In contrast to
the negative regulators, co-receptors for BMP ligands can enhance
their signalling. Repulsive guidance molecules (RGMs, A, B and C)
can enhance signalling of BMP2 and BMP4 as co-receptors [60–62].
I-Smads suppress TGF-β signalling by either preventing R-Smad
activation or competitively binding with Smad4 to block the for-
mation of Smad hetero-complex [63,64]. Smad7 can target both TGF-
β/activin and BMP signalling, whilst Smad6 is more speciﬁc for BMP
signalling [63,65]. Such inhibitory effects of I-Smads can be en-
hanced when cells are exposed to BMP ligands due to feedback
regulations [66,67]. The action of I-Smads can be ﬁne-tuned by an
association with the SH3 domain of STAM (AMSH) which can di-
rectly bind to Smad6 and thus interferes with the interactions
between Smad6 and the activated BMP type I receptors [68]. To reg-
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ulate gene transcription, Smad-1, -5 and -8 need assistance from
other transcription factors due to their low aﬃnity in binding with
SBEs. These helpers include Forkhead box HI (FOXHI) [69], P53 [70],
Runx transcription factors [71], Smad interacting protein-1 (SIP-1)
[72] and ATF-2 [73]. Transcriptional co-activators and repressors are
also involved in the regulation of Smad signalling. P300 and CREB-
binding protein (CBP) can enhance transcriptional activities of Smads
[74]. Sloan-Kettering retrovirus (Ski) can inhibit BMP signalling via
interaction with Smad-1, -3, -5 and -4 [75–77]. The transcrip-
tional activities can also be balanced between BMPs and other TGFβ
family members. For example, Ski and SnoN degradation can be trig-
gered by TGFβ signalling which may thus enhance Smads-induced
transcription [78]. In addition, Smads in the intracellular pool are
also regulated by HECT type E3 ligases known as Smad Ubiquitination
Fig. 1. BMP signal transduction. (A) BMP signalling pathways. BMP ligands bind to type I and type II simultaneously which leads to activation of the Smad-dependent pathway.
Activation, transport and regulation of target genes by R-Smads require Co-Smad. If BMP ligands bind to the type I receptors ﬁrst and then recruit the type II receptors
which activatesTAB1/2/3 through XIAP, this would lead to the activation of Smad independent MAPK pathway. Regulation of BMP signaling can occur extracellularly during
the process of ligand binding to receptor, and intracellularly during the signal transduction. (B) BMPs and their speciﬁc receptors. Key downstream signalling molecules of
BMP/GDF through the use of a dendrogram tree. Phylogenetic analysis was performed using the Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/), and the den-
drogram tree was plotted using the Treeview (Version 1.6.6, http://taxonomy.zoology.gla.ac.uk/rod/treeview.html).
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Regulatory Factors (Smurf) 1 and 2. Smurf 1 can either directly
interact with Smad 1/5 to facilitate their degradation [79] or indi-
rectly interact with the BMP type I receptor through I-Smad 6 and
7 leading to a degradation of the receptors [80]. Smurfs also par-
ticipate in the translocation of I-Smads from the nucleus into the
cytoplasm and enhance I-Smad interaction with the type-I recep-
tors [81]. NEDD4-2 (neural precursor cell expressed, developmentally
down-regulated 4-2) which is structurally similar to Smurfs can di-
rectly bind with Smad-2, -3 and -7 leading to degradation of these
proteins [82,83].
Aberrant BMP signalling in cancer
Since BMPs play profound roles in the bone formation and reg-
ulation of cell differentiation, their involvement in tumourigenesis
and cancer progression has been a hot spot for cancer research. Ab-
erration in BMP expression and their signalling has been observed
in a variety of solid tumours and disease speciﬁc bone metastasis
[18].
Dysregulated BMP and BMP signalling at the primary tumour
Breast cancer and prostate cancer have been intensively studied
for the involvement of BMPs in their disease progression due to the
unique feature of their metastasis to bone. They are the leading
cancers seen in women and men respectively in developed coun-
tries. BMP-6 overexpression is associated with higher grade, primary
tumours and advanced prostate cancer with metastasis [84–87].
BMP-6 may also play a role in the progression of androgen inde-
pendent prostate cancer [85,87]. Downregulated expression of BMP-
2, BMP-4, BMP-7, BMP-9, BMP-10 and GDF15 has been observed in
prostate cancer during its development and progression [88–94].
Similarly, reduced expression of BMPs, including BMP-2, BMP-4,
BMP-6, BMP-7, BMP-12, BMP15 and GDF9a, has been evident in
breast cancer and is associated with poor prognosis of the pa-
tients [95–97]. Although the expression of speciﬁc BMPs, such as
BMP-2, 4, 6 and 7, in breast cancer remains controversial [95,98–101],
the aberrant BMP expression plays a role in the development and
progression of both prostate and breast cancers.
The expression of BMPRIA, BMPRIB, and BMPRII in human pros-
tate cancer tissues is frequently reduced – or absent – from high-
grade (poorly differentiated) prostate tumours which plays an
important role in the disease progression [92,102–104]. Elevated ex-
pression of BMPR-IB was associated with high tumour grade, high
tumour proliferation, cytogenetic instability, and a poor prognosis
in oestrogen receptor-positive carcinomas [105]. Decreased levels
of BMPR-1B have also been observed in breast cancer, which are
associated with poorer prognosis [106].
Perturbed Smad expressions and signalling have also been in-
dicated in the primary tumours. Loss of Smad 4 is related to the
progression of prostate cancer towards a more aggressive pheno-
type suggesting that it is a tumour suppressor [90]. Activation of
the Smad pathway of BMPs (Smad1/5/8) and TGF-β (Smad2) has
also been reported in breast cancer cells in both primary tumours
and bone metastases [107].
BMP in bone metastasis
Primary prostate tumours and metastatic prostate tumours
exhibit differential expression proﬁles of BMP and BMP signalling
molecules. The differential expression has an intimate relation-
ship with the disease progression, in particular the bonemetastases.
BMP6 is highly expressed by both primary prostate tumours and
metastatic bone lesions. In contrast, BMP7 and GDF15 are sup-
pressed in prostate cancer cells at primary tumours and are
upregulated in the metastatic cancer cells at bone lesions [89,108].
Decreased expression of BMP7 in primary tumours is associatedwith
bonemetastases. BMP7 is able to inhibit the growth of breast cancer
tumours at primary sites and in bone in vivo [109]. BMP-2 can
promotemetastasis of breast cancer cells to bone [110]. On the other
hand, lack of BMP antagonists in breast cancer may contribute to
the osteoblastic lesions of breast cancer [111]. A more recent study
also demonstrated that lack of Noggin expression in both breast and
prostate cancer cells was associated with osteoblastic activities in
bone metastases. However, targeting Noggin was able to reduce os-
teoblastic activity, but had little inﬂuence on bone resorption and
tumour growth [112]. Meanwhile, increased expression of BMP re-
ceptors and activation of BMP signalling have also been implicated
in breast cancer and the corresponding bone metastasis from the
tumour. Activation of the Smad pathway of BMPs (Smad1/5/8) and
TGF-β (Smad2) has been revealed in the nuclei of breast cancer cells
at both primary tumours and bone metastasis [107]. These studies
collectively suggest that BMPs are involved in bone metastasis.
Since metastatic cancer cells spread to the bone, interactions
between the tumour cells and its residing microenvironment con-
stantly affect the subsequent development of a secondary tumour.
Such a crosstalk coordinates functions of cancer cells and host cells.
BMPs released from tumour cells inﬂuence remodelling of the bone
by regulating osteoblastic and osteoclastic activity. Such mutual in-
ﬂuence is also reﬂected by the BMPs that are enriched in the bone
environment. In addition to the promotion of the motility and in-
vasion of cancer cells, they are also able to induce the expression
of other growth factors, which then enhances the vicious circle of
bone–tumour–bone interactions. For example, BMP2 induced
osteoprotegerin (OPG) expression in PC-3 cells inhibits
osteoclastogenesis which may contribute to the osteoblastic lesions
[113]. BMP-7 induces VEGF expression in prostate cancer cells, which
leads to an enhanced pro-osteoblastic activity in the tumour [114].
Taken together, aberrant expression of BMPs and BMP signal-
ling molecules has been implicated in a variety of solid tumours
and disease speciﬁc bone metastasis. Most BMPs elicit inhibitory
effects on proliferation of cancer cells through their receptor sig-
nalling. Certain BMPs, including BMP-2 and BMP-7, can promote
epithelial mesenchymal transition (EMT) and enhance cell inva-
sion and motility, leading to a more aggressive phenotype and
contribute to the subsequent dissemination of cancer cells [115,116].
On the other hand, contrasting evidences also showed that BMPs,
for example, BMP-6 and BMP-7, were able to reverse EMT and inhibit
aggressive traits of cancer cells [56,94,109,117]. The phenotypic
proﬁle of BMPs, BMP receptors and intracellular signalling mol-
ecules can be modiﬁed by sexual hormones and growth factors in
order to coordinate biological behaviours of cancer cells during the
disease progression. The altered expression of certain BMPs may
assist cancer cells to metastasise to bone. In addition to their direct
effect on cancer cells, BMPs can also regulate angiogenesis thus in-
directly contributing to tumour growth and metastasis (Fig. 2).
BMP and angiogenesis
Angiogenesis is critical for the development and progression of
both primary and secondary tumours. It has been demonstrated that
BMPs, including BMP-2, 4, 6, 7 and GDF5, are capable of inducing
angiogenesis [118–121]. BMP receptors play an important role in
mediating the angiogenesis induced by BMPs. For example, BMPR-
IB and BMPR-II are upregulated in endothelial cells during tubule
formation [122], whilst activation of ALK1/Smad-1/5 pathway
induces angiogenesis, whereas ALK5/Smad-2/3 pathway signal-
ling is involved in the angiogenesis at a later stage [123]. In addition
to BMP ligands and their receptors, BMP antagonists are also in-
volved in angiogenesis. Gremlin for example shows higher expression
in pituitary tumours and is associated with angiogenesis [124].
However, Gremlin may directly target vascular endothelial cells to
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promote angiogenesis rather than interactingwith BMP ligands [125].
Tumour associated angiogenesis is orchestrated by interactions
among cancer cells with the local microenvironment at both primary
tumour and secondary tumour. In the following text, the way that
BMPs directly act on the vascular endothelial cells and also what
roles they play in the orchestrated angiogenesis in tumours will be
highlighted.
Direct effect of BMP on vascular endothelial cells
The direct effect on endothelial cells by certain BMPs, such as
BMP-2, -4 and -9, has been recently reviewed, speciﬁcally for their
implication in endothelial dysfunction and corresponding vascu-
lar diseases other than tumours [126]. In addition to their potent
effect on bone formation, BMP-2, 4, 6, 7 and GDF-5 can also promote
angiogenesis [118–121]. For example, GDF-5 exhibited pro-
angiogenic effect in a chorio-allantoic membrane (CAM) assay, but
not for BMP-2 [118]. However, BMP-2 can promote angiogenesis in
an in vivo lung cancer tumour model [127]. BMP-2 promotes mi-
gration and tubule formation of human umbilical vein endothelial
cells with little effect on proliferation and apoptosis [128]. BMP-2
can also suppress expression of apelin in vascular endothelial cells
which may have profound implication during angiogenesis [129].
Disable homolog 2 (Dab2) has been revealed as an important factor
in BMP-2 induced angiogenesis. It provides a molecular basis for
understanding the context-dependent proangiogenic function of BMP
signalling [130]. During caudal vein plexus (CVP) formation in
zebraﬁsh, BMP induces the extension of endothelial ﬁlopodia and
their migration via Arhgef9b-mediated activation of Cdc42. Active
Cdc42 binds to and stimulates Formin-like 3 (an actin-regulatory
protein of the formin family) which, in turn, promotes angiogenic
sprouting of the CVP [131]. BMP-2 can also promote proliferation
of aortic endothelial cells [127] and stimulate migration of vascu-
lar smooth muscle cells [132]. A similar effect on smooth muscle
cell migration has also been observed for BMP-4 and BMP-7
[133,134]. It suggests that BMPs can regulate angiogenesis by co-
ordinating different cells.
Being different from other BMPs, BMP-9/-10 exhibit an inhibi-
tory effect on angiogenesis by suppressing proliferation andmigration
of endothelial cells [135]. BMP-9/ALK1-induced CV2 and matrix Gla
protein (MGP) can inhibit the angiogenic effect of BMP-4 by dis-
rupting complex formation between BMP-4 and BMP-9, and their
receptors ALK2 and ALK1 [136]. Furthermore, BMP-9 can inhibit
lymphangiogenesis via ALK-1 during development and cancer pro-
gression [137].
Endothelial cells cultured on type-I collagen can spontane-
ously form tubular structures which exhibit increased expression
of BMPR-IB and BMPR-II. The CAM assay also showed the impor-
tant role played by these BMP receptors in angiogenesis [122].
Downstream of BMP receptors, Smads play a vital role in mediat-
ing signal transduction for BMPs. Smads are the transcriptional
regulators of BMP target genes, in particular the VEGF. Smad3 ex-
pression in rat proximal tubular cells resulted in an induction of
endothelial cell proliferationwith an up-regulation of VEGF-A, whilst
Smad2 induced expression of thrombospondin-1 – this suggests that
these two Smads have opposing roles during angiogenesis [138].
However, Smad-3 in a gastric cancer cell line (SNU484) gastric cancer
cells results in a down-regulation of VEGF expression. Smad-3 also
suppresses in vivo growth of these cancer cells with impaired an-
giogenesis [139]. Overexpression of Smad-4 pancreatic cancer cells
suppresses VEGF expression and up-regulates thrombospondin-1
expression leading to reduced new vasculature [140].
BMP antagonists play important roles in justiﬁcation of cell re-
sponse to BMP ligands. Noggin can attenuate the pro-angiogenic
effect of BMP-7 [114]. Drm/gremlin has been identiﬁed as a pro-
angiogenic factor expressed by endothelium through promoting
migration and invasion. Interestingly, BMP4 does not affect the pro-
angiogenic effect of Drm/gremlin, instead, the two work together
to promote angiogenesis in vitro and in vivo. It suggests that Drm/
gremlin can interact directly with endothelial cells to modulate
angiogenesis in a relatively independent manner [125]. Higher ex-
pression of Gremlin has also been revealed in pituitary tumours
which is associatedwith angiogenesis [124]. In a study of lung cancer,
BMP-9 and Follistatin were used as angiogenic biomarkers for as-
Fig. 2. BMP in cancer and cancer metastasis. Dysregulated BMP signalling assist cancer cells dynamically during the development and disease progression, in particular
during angiogenesis.
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sisting differential diagnosis of malignant tumours from benign
tumours. BMP-9 is elevated in malignant tumours whilst Follistatin
is decreased [141]. BMP-binding endothelial cell precursor-derived
regulator (BMPER) can regulate migration of endothelial cells in a
dose-dependent manner, i.e. a promoting effect at lower concen-
tration and an inhibitory effect at higher concentration [142]. Tsg
and BMPER interfere with each other to enhance their angiogenic
effect [143]. BMPER-coordinated BMP-4 signalling relies on LDL
receptor-related protein 1 (LRP1), mediated endocytosis, and sub-
sequent Smad activation [144].
BMP-mediated angiogenic effect in the crosstalk between tumour cell
and local microenvironment
The process of angiogenesis is regulated by altering the balance
of pro-angiogenic and anti-angiogenic factors. One of the most well-
known pro-angiogenic factors is VEGF, which is frequently over-
expressed in cancers and can be regulated by many signalling
pathways, including TGF-β and BMP [145]. BMP-9 for example, when
signalling via ALK-1 and BMPR-II in endothelial cells, activates
Smad1/5 downstream signalling and has been shown to inhibit the
proliferation of endothelial cells, as well as block VEGF mediated
angiogenesis [146]. Secretion of BMP and angiogenic factors comes
from different cell types in a tissue. An in vitro 3D cell model com-
prising adipose-derived stromal cells and endothelial cells revealed
such differential resources for these soluble factors [147].
The experimental evidence suggests that BMPs can promote an-
giogenesis indirectly through up-regulation of the expression of VEGF
in both cancer cells and osteoblasts. Dai et al. have demonstrated
that it is possible for BMP-7 to promote osteosclerosis through VEGF
in the skeletal metastases from prostate cancer [114]. BMP-7 can
also upregulate VEGFR in vascular endothelial cells [148]. BMP-2
up-regulates VEGF through p38 pathway human adipose derived
stromal cells [149]. Bone induction by rhBMP-2 can be blocked by
the anti-angiogenic agent (TNP-470) [119]. These pieces of evi-
dence suggest that angiogenesis is an integrated part of BMP induced
bone formation.
BMP-induced angiogenesis can also be synergised by basic ﬁ-
broblast growth factor (bFGF) and TGF-β1 [150]. This synergistic
effect on angiogenesis has also been observed for BMP-2 and VEGF
in electron beam melting-fabricated porous titanium implant de-
livery of these factors for orthopaedic application [151]. In human
bone marrow stromal cells (hBMSCs), BMP-5 and -6 can upregulate
SDF-1, BMP-2 induces b-FGF, whilst VEGF can be up-regulated by
BMP-2 and -4 [152]. In contrast to TGF-β1 and most BMPs, BMP9
has been shown to inhibit the proliferation of endothelial cells, as
well as block VEGF mediated angiogenesis [146].
Cross talk between Delta-like ligand 4 (DLL4)-notch and BMP sig-
nalling plays a critical role in the tip-stalk formation during
angiogenesis [153]. BMP-9 and BMP-10 can upregulate the expres-
sion of genes involved in Notch signalling (Jagged 1, DLL4, Hey1, Hey2
and Hes1) in vascular endothelial cells thus coordinating postna-
tal vascular remodelling [154]. ALK1 mediated BMP signalling can
regulate Hey1 and Hey2, but not other Notch target genes (Hes1,
Hes5, ephrinB2 and DII4) [155]. VEGF and DII4/Notch signalling op-
erates through a negative feedback loop that regulates endothelial
tip and stalk cells to ensure adequate vessel branching and func-
tion. Neuropilin-1 (Nrp1) suppresses the stalk cell phenotype by
limiting Smad2/3 activation through ALK1 and ALK5. Notch
downregulates Nrp1 leading to a relief of ALK1 and ALK5 medi-
ated Smad signalling [156]. Osterix (Osx) is a BMP-2 inducible
osteoblast speciﬁc transcription factor which is essential for osteo-
blast differentiation and bone formation. Proline-rich regions of Osx
are important for its binding to the VEGF promoter and conse-
quent up-regulation of VEGF. Osx and HIF-1alpha can cooperatively
regulate VEGF expression [157]. CXXC5 containing CXXC-type zinc-
ﬁnger is a transcription factor of Flk-1. It can mediate BMP signalling
for differentiation andmigration of vascular endothelial cells during
angiogenesis and vascular development [158].
Hepatocyte growth factor (HGF) and its receptor, cMet signal-
ling, plays a vital role in tumour angiogenesis and has been a target
for the research of anti-angiogenesis [159–161]. HGF can up-
regulate the expression of BMP-7 and BMP receptors in prostate
cancer cells [162,163]. Our recent study also showed that HGF was
able to upregulate BMP coreceptor (RGMb) in vascular endothelial
cells which mediated HGF and BMP-7 induced angiogenesis [164].
It suggests that HGF/BMP-7 may work together to enhance angio-
genesis in tumours. Smad-2, -3 and -4 can also mediate differential
regulation on HGF transcription. Smad-2 binds with higher aﬃn-
ity with co-repressors of HGF promoter, whilst Smad-3/Smad-4 are
more likely to work together with a co-activator. Therefore, target-
ing different Smads could elicit contrasting effects on HGF promoted
angiogenesis [165].
BMP Smad signalling can also upregulate the expression of
platelet-derived growth factor alpha (PDGFA) during glanulosa cell
tumourigenesis [166]. BMP-2 and ﬁbrin-binding platelet-derived
growth factor-BB (PDGF-BB) can promote the formation of bone and
new vasculature [167]. BMP-4 stimulated ﬁbroblasts can release
more inﬂammatory factors and MMPs [168]. BMP-4 suppress TNF
induced expression of MMP-9 through the Smad dependent pathway
[169].
A microenvironment can foster interactions between cancer cells
and other types of cell to promote angiogenesis. TGF-β plays an im-
portant role in the crosstalk within the tumour microenvironment
including interactions among stromal cells, endothelial cells and
tumour cells. Stromal cell-released TGF-β induces both ligand-
dependent and ligand-independent activation of androgen receptor
(AR) in prostate cancer cells through an up-regulation of BMP-6 and
IL-6 [170]. Extracellular matrix is also involved in orchestrated an-
giogenesis. Culturing on type-I collagen can promote spontaneous
formation of tubular structures by endothelial cells via up-regulated
levels of BMPR-IB and BMPR-II expression [122]. Enamel matrix de-
rivative (EMD) can promote angiogenesis and osteogenesis. Low
molecular weight protein pools (7–17 kDa) of EMD can induce BMP
signalling and increase osterix and VEGF-A expression [171]. VEGF
and FGF-2 are more helpful in the initial activation phase during
the angiogenesis process, whilst BMP-2 can synergistically work to-
gether with these two angiogenic factors in a more effective way
by delivering at the maturation stage [172]. BMP-2 and ﬁbrin-
binding platelet-derived growth factor-BB (PDGF-BB) can promote
the formation of bone and new vasculature [167]. Pregnancy-
associated plasma protein-A2 (PAPP-A2, pappalysin-2) is a large
metalloproteinase, known to be required for normal postnatal growth
and bone development in mice. Papp-a2 regulates BMP signalling
via a proteolysis of insulin-like growth factor binding protein-3
(IGFBP-3) and also Notch signalling by an independent mecha-
nism [173].
Bonemarrow stem cells (BMSCs) implantedwith porous silk scaf-
folds (silk ﬁbroin) can differentiate into endothelial cells and
osteoblasts in the presence of VEGF and BMP-2 [174]. Localised
release of VEGF and BMP-2 can promote bone regeneration, in part
by facilitating the mobilisation of bone marrow stem cells and the
subsequent differentiation into endothelial and osteogenic lin-
eages respectively [175]. BMP-6 can induce IL-1alpha inmacrophages
through a cross-talk between NF-kappaB and Smad1 signalling
leading to an action on endothelial cells [176]. In BMP-2 induced
bone formation, αSMA+ and Tie2+ progenitor lineages make dis-
tinct cellular contributions to bone formation, angiogenesis, and
resorption/remodelling. Co-staining of tartrate-resistant acid phos-
phatase activity (TRAP, an osteoclast marker) and CD31 (vascular
endothelia marker) was seen in the Tie2-lineage endothelial pro-
genitor cells, whilst the αSMA-lineage cells contribute to osteoblastic
591L. Ye, W.G. Jiang / Cancer Letters 380 (2016) 586–597
lineage [141]. FGF-2 can up-regulate BMP-2 to promote osteoblas-
tic differentiation and bone formation in periodontal regeneration
[177]. These pieces of evidence have opened up an avenue leading
to a better understanding of complicated interactions among dif-
ferent cell types in bones during bone formation and angiogenesis,
which is vital for tumour associated angiogenesis and bone me-
tastasis (Fig. 3).
Therapeutic potential by targeting BMPs and their signalling
The variety of effects exhibited by some BMPs offer us with dif-
ferent choices of approach. We would then use these molecules for
tumour associated angiogenesis. For example, BMP-2, -4, -6, -7 and
GDF-5 are pro-angiogenic factors, whilst BMP-9 and -10 are anti-
angiogenic factors. The natural BMP antagonist, Noggin, can be used
to target pro-angiogenic BMPs. In contrast, recombinant BMP-9 and
-10 can be used to suppress angiogenesis. BMP-9 and BMP-10 have
both also shown inhibitory effects on growth and motility of certain
cancer cells [92,93,178]. On the other hand, attenuation of BMP-9
induced ALK1 signalling with neutralising antibody was able to
inhibit endothelial cell sprouting [179]. It suggests that ALK1 can
be targeted for prevention of tumour associated angiogenesis. PF-
03446962 (Pﬁzer) and Dalantercept (also known as ACE-041,
Acceleron Pharma) targeting ALK1 have been shown as potent in-
hibitors for blocking development of blood vessels. PF-03446962
is a monoclonal antibody against ALK1 which exhibits a dose-
dependent anti-angiogenic activity [180]. Dalantercept is a soluble
chimeric protein (ALK1-Fc) which displays high aﬃnity binding with
BMP-9 and BMP-10 and therefore suppresses tumour growth by in-
hibiting angiogenesis [181]. Both are currently being tested as anti-
angiogenic agent alone or in conjugation with other anti-angiogenic
or anti-cancer agents in different clinical trials to treat advancedma-
lignancies and treat/prevent metastatic tumours (Table 1). A recent
study showed that targeting ALK1 using a small molecule inhibi-
tor (K02288) was able to inhibit angiogenesis through suppressing
signalling of both Smad and Notch pathways [182]. However, anti-
angiogenic potential of the small inhibitor is yet to be examined in
clinical trials. BMP signalling is required for remodelling of plexus
into structured blood vessels during zebraﬁsh ﬁn regeneration. In-
hibition of BMP signalling using DMH1 blocksmaturation of the new
vasculature [183]. Endoglin also known as CD105, mediates a tran-
sition of endothelial cells from quiescent to active status during
angiogenesis through preferential phosphorylation of Smad 1/5/8
(endoglin is also a coreceptor for BMP-9). A monoclonal antibody
against Endoglin (TRC105) has exhibited anti-angiogenic poten-
tial and may achieve greater effect in a combination with
bevacizumab. TRC105 is currently being tested in phase 1b and phase
2 clinical trials [184] (Table 1).
The expression of BMP-7 for example is decreased or absent from
primary tumours which may be related to the shift in phenotype
from androgen-dependent to androgen-independent activity within
the cancer cells [91]. Loss of endogenous BMP-7 may encourage the
prostate cancer cells to be more aggressive [56]. However, BMP-7
can be re-expressed in metastatic cancer cells in bone [108]. This
needs to be considered when we select BMP for targeting cancer
cells and angiogenesis.
The VEGF pathway is critical for tumour angiogenesis. However,
anti-angiogenic therapy targeting VEGF can be limited by intrinsic
and acquired resistance. Understanding of BMP for its implication
in tumour associated angiogenesis may provide more targets. We
wish to ﬁll the therapeutic gap of solely targeting the VEGF pathway.
Alternative targets can be selected from BMP signalling as afore-
mentioned. Furthermore, HGF is a key cytokine in promoting cancer
metastasis and angiogenesis. Our recent studies have demon-
strated that HGF can up-regulate the expression of BMP-7 and BMP
receptors in prostate cancer cells, and RGMb in vascular endothe-
lial cells [162–164]. Targeting HGF and BMP signalling may prevent
tumour associated angiogenesis. Collectively, these will provide a
Fig. 3. BMP in orchestrated tumour angiogenesis. Multiple cell types exist in a tumour, a vicious tri-angle can be triggered by the cancer cells. BMPs play a vital role in
these types of crosstalk and resulted in a promoted angiogenesis which can facilitate tumour growth and dissemination.
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comprehensive understanding of how angiogenesis is instigated in
the tumour and what should be considered for personalised disease
management.
A recent review has summarised the mechanism leading to in-
creased endothelial cell growth and angiogenesis with a focus on
miR-26 [185]. MiR-26a expression is decreased by pro-angiogenic
stimuli such as VEGF, bFGF, and TNF-α in endothelial cells (ECs). MiR-
26a inhibits SMAD1 by binding to its 3′-UTR, leading to a down-
regulation of ID1 and an increased expression of p21WAF1/CIP1 and
p27. In addition, MiR-885-3p can interact with BMPR1A and con-
sequently results in an inhibition of Smad 1/5/8 signalling and
downregulation of ID-1 leading to impaired angiogenesis [186]. It
suggests that these microRNAs have a certain anti-angiogenic po-
tential yet to be fully examined.
Above all, BMPs and their signalling pathways play critical roles
in the development, progression, and metastasis of various cancers.
Together with their involvement in angiogenesis, promising targets
should be fully investigated for their therapeutic potential.
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